Manchester Capital Management LLC Has $397,000 Holdings in CME Group Inc. (NASDAQ:CME)

Manchester Capital Management LLC grew its position in CME Group Inc. (NASDAQ:CME) by 14.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,498 shares of the financial services provider’s stock after purchasing an additional 188 shares during the quarter. Manchester Capital Management LLC’s holdings in CME Group were worth $397,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CME. Bank Pictet & Cie Europe AG grew its position in CME Group by 29.0% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 86,941 shares of the financial services provider’s stock worth $20,190,000 after buying an additional 19,533 shares in the last quarter. Landscape Capital Management L.L.C. grew its position in CME Group by 59.3% during the fourth quarter. Landscape Capital Management L.L.C. now owns 2,061 shares of the financial services provider’s stock worth $479,000 after buying an additional 767 shares in the last quarter. Prudential PLC grew its position in CME Group by 55.1% during the fourth quarter. Prudential PLC now owns 18,941 shares of the financial services provider’s stock worth $4,399,000 after buying an additional 6,727 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in CME Group during the fourth quarter worth approximately $26,758,000. Finally, Envestnet Asset Management Inc. lifted its stake in CME Group by 1.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 552,108 shares of the financial services provider’s stock worth $128,216,000 after purchasing an additional 7,525 shares during the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

Insider Activity at CME Group

In other news, Director Phyllis M. Lockett sold 1,060 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $277.88, for a total transaction of $294,552.80. Following the completion of the sale, the director owned 3,108 shares in the company, valued at $863,651.04. This trade represents a 25.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel G. Kaye sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total transaction of $141,210.00. Following the sale, the director owned 3,668 shares of the company’s stock, valued at approximately $1,035,916.56. The trade was a 12.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,750 shares of company stock worth $1,576,294 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CME shares. JPMorgan Chase & Co. cut their target price on CME Group from $223.00 to $211.00 and set an “underweight” rating for the company in a research note on Thursday, April 24th. UBS Group reiterated a “neutral” rating and set a $305.00 price target on shares of CME Group in a report on Thursday, July 24th. Barclays set a $298.00 price target on shares of CME Group and gave the stock an “equal weight” rating in a report on Thursday, July 24th. Morgan Stanley upped their price target on shares of CME Group from $301.00 to $304.00 and gave the stock an “overweight” rating in a report on Thursday, April 24th. Finally, Piper Sandler upped their price target on shares of CME Group from $283.00 to $296.00 and gave the stock an “overweight” rating in a report on Tuesday, July 15th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $261.93.

CME Group Stock Performance

Shares of CME Group stock opened at $280.76 on Monday. The company has a market cap of $101.18 billion, a P/E ratio of 27.18, a PEG ratio of 4.99 and a beta of 0.44. The business has a 50-day moving average price of $276.07 and a two-hundred day moving average price of $264.36. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 1-year low of $196.62 and a 1-year high of $290.79.

CME Group (NASDAQ:CME) last announced its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.91 by $0.05. CME Group had a net margin of 58.48% and a return on equity of 14.60%. The business had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter last year, the firm earned $2.56 EPS. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, analysts anticipate that CME Group Inc. will post 10.49 EPS for the current year.

CME Group Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were paid a dividend of $1.25 per share. The ex-dividend date was Monday, June 9th. This represents a $5.00 annualized dividend and a dividend yield of 1.8%. CME Group’s dividend payout ratio (DPR) is presently 48.40%.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.